第二剂加强针可降低新冠感染后长新冠风险:巴西东南部多中心研究
该多中心观察性研究纳入巴西东南部2033名既往感染SARS-CoV-2者,67%报告长新冠症状;女性、合并症、再感染和急性重症为独立危险因素,接种两剂加强针与长新冠风险显著降低相关(OR 0.18,95%CI 0.07-0.46,p<0.001)。
要点
- 两剂加强针与长新冠风险显著降低相关(OR 0.18,95%CI 0.07-0.46)。
- 女性、合并症、再感染和急性重症是长新冠独立危险因素。
- 奥密克戎期亚组中仅第二剂加强针显示保护作用(OR 0.50)。
核心结论
- COVID-19疫苗接种,尤其是两剂加强针,可降低长新冠风险。
- 女性、合并症、再感染和急性重症是长新冠的独立危险因素。
研究设计与样本
- 多中心观察性研究,对既往感染SARS-CoV-2者进行横断面分析。
- 纳入巴西圣保罗和里约热内卢五家医疗中心共2033名参与者,医护人员占86%。
- 通过标准化电子问卷收集临床数据和长新冠症状,采用多因素logistic回归评估预测因素。
主要发现
- 2033名参与者中67%(1370人)报告长新冠症状。
- 女性长新冠风险OR 2.25(95%CI 1.81-2.79,p<0.001)。
- 有1、2、≥3种合并症者OR分别为1.74(95%CI 1.36-2.23)、2.14(95%CI 1.43-3.20)、3.10(95%CI 1.55-6.19)。
- 再感染1次和≥2次者OR分别为2.35(95%CI 1.84-3.01)和4.22(95%CI 2.043-7.91)。
- 急性重症OR 1.91(95%CI 1.09-3.35,p=0.02);两剂加强针OR 0.18(95%CI 0.07-0.46,p<0.001)。
关键数值与推荐
- 奥密克戎期亚组中,与完成基础免疫相比,第二剂加强针OR 0.50(95%CI 0.34-0.74,p<0.001)。
- 奥密克戎期亚组中,单剂加强针未显示显著保护作用。
临床怎么用
- 对既往感染者应评估长新冠风险,重点关注女性、有合并症、再感染史或急性重症者。
- 在疫苗策略中,两剂加强针可能有助于降低长新冠风险。
局限性
- 横断面设计可能限制因果推断。
- 长新冠症状通过电子问卷自我报告,可能存在信息偏倚。
- 医护人员占参与者的86%,可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Long COVID is a complex condition with diverse symptoms, lacking specific diagnostic or therapeutic tools. Although vaccination reduces the risk of severe COVID-19, its role in preventing long COVID, particularly through booster doses, remains limited. This study assessed the impact of first and second booster doses and identified long COVID risk factors. METHODS: We conducted a multicenter observational study with a cross-sectional analysis of participants previously infected with SARS-CoV-2 during the pre-Omicron and Omicron epidemiological periods. Both periods included mixed populations of healthcare workers (HCWs) and non-HCWs, with HCWs representing 86% of all participants. The study included five medical centers in São Paulo and Rio de Janeiro. Clinical data and long COVID symptoms were collected through a single standardized electronic questionnaire sent to all eligible participants. Predictors of long COVID were evaluated using multivariable logistic regression. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. RESULTS: A total of 2033 participants were included, and 67% (1370) reported long COVID symptoms. Independent risk factors included female sex (OR 2.25, 95% CI 1.81-2.79, p < 0.001), the presence of one, two, or three or more comorbidities (OR 1.74, 95% CI 1.36-2.23, p < 0.001; OR 2.14, 95% CI 1.43-3.20, p < 0.001; and OR 3.10, CI 1.55-6.19, p = 0.001, respectively); the occurrence of one or more reinfections (OR 2.35, 95% CI 1.84-3.01, p < 0.001; and OR 4.22, 95% CI 2.043-7.91, p < 0.001, respectively), and a severe acute illness (OR: 1.91; 95%CI 1.09-3.35; p = 0.02). Vaccination was protective, with the strongest effect observed among those receiving two booster doses (OR: 0.18; 95% CI 0.07-0.46; p < 0.001). In the Omicron period sub-analysis, only the second booster dose was associated with reduced risk compared with a complete primary series (OR 0.50, CI 0.34-0.74, p < 0.001), whereas one booster dose showed no significant effect. CONCLUSION: COVID-19 vaccination, especially two booster doses, reduced long COVID risk. Female sex, comorbidities, reinfections, and severe acute illness were independent risk factors for developing long-lasting symptoms.
引用
- Barboza APB, Luna-Muschi A, Faffe D, et al. Protective effect of a second booster dose against long COVID among individuals infected with SARS-CoV-2 in southeastern Brazil. Vaccine. 2026. PMID: 41713328. doi:10.1016/j.vaccine.2026.128354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。